

Coalition Agreement Presented by CDU/CSU and SPD**Sanity Group Welcomes Planned Evaluation of Cannabis Law and Calls for Timely Launch of Scientific Pilot Projects**

Berlin, April 9, 2025 – The coalition agreement presented today by CDU/CSU and SPD includes an important announcement for the German cannabis industry: The new government plans an unbiased evaluation of the Cannabis Act in autumn 2025, which came into force in April 2024. The aim is to review the current state of the regulated handling of cannabis and, if necessary, make adjustments. Berlin-based cannabis company Sanity Group welcomes this step – and simultaneously calls for the timely approval of scientific pilot projects for the regulated distribution of recreational cannabis.

"It is the right step that the coalition intends to evaluate the Cannabis Act as planned, to assess how the partial legalization has impacted issues such as youth protection, public health, and fighting the illicit market," says Finn Age Haensel, founder and CEO of Sanity Group. "At the same time, it is crucial to fully implement the law first. That is why we call for the prompt approval of scientific pilot projects for the distribution of recreational cannabis through licensed specialty stores. These will allow us to gain new insights based on solid data and practical experience. Only through a data-driven and scientifically grounded analysis can we implement the right measures to establish a quality-assured and responsible cannabis market while minimizing health risks to the population."

Ensuring Medical Care: Cannabis Patients in Focus

In the field of medical cannabis, Sanity Group calls for continuous improvements in supply security. "The needs of patients must continue to be front and center. We advocate for widespread, low-threshold access to medical cannabis therapy that consistently upholds the highest standards of quality and safety," explains Haensel. "Medical treatment with cannabis-based medicines should be made as accessible and straightforward as possible for all who need it."

With the evaluation of the Cannabis Act, the new government is sending a clear signal for an evidence-based approach to recreational cannabis. Sanity Group is convinced that the introduction of scientific pilot projects will promote the responsible distribution of cannabis and pave the way for a modern drug policy.

About Sanity Group

Sanity Group aims to improve people's quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed and avayay Medical (medical cannabis), Endosane Pharmaceuticals (pharmaceuticals), vaay (lifestyle) and Grashaus Projects (Swiss pilot project on recreational cannabis). Near Frankfurt am Main, Sanity Group also operates a production and logistics facility for cannabinoid-based medical products. More information at sanitygroup.com/press.